Incidence of Hospitalisation for Heart Failure and Case-Fatality Among 3.25 Million People with and without Diabetes by McAllister, David A. et al.
 
 
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Incidence of Hospitalisation for Heart Failure and Case-Fatality
Among 3.25 Million People with and without Diabetes
Citation for published version:
McAllister, DA, Read, SH, Kerssens, J, Livingstone, S, McGurnaghan, S, Jhund, P, Petrie, J, Sattar, N,
Fischbacher, C, Kristensen, SL, McMurray, J, Colhoun, HM & Wild, SH 2018, 'Incidence of Hospitalisation
for Heart Failure and Case-Fatality Among 3.25 Million People with and without Diabetes', Circulation, vol.
138, no. 24, pp. 2774–2786. https://doi.org/10.1161/CIRCULATIONAHA.118.034986
Digital Object Identifier (DOI):
10.1161/CIRCULATIONAHA.118.034986
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Circulation
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 04. Jan. 2021
10.1161/CIRCULATIONAHA.118.034986 
1 
Incidence of Hospitalisation for Heart Failure and Case-Fatality Among 3.25 
Million People with and without Diabetes 
 
Running Title: McAllister et al.; Diabetes, Heart Failure Hospitalization and Death 
 
David A McAllister, MD1,2; Stephanie Read, PhD3; Jan Kerssens, PhD2;  
Shona Livingstone, MSc4; Stuart McGurnaghan, BSc5; Pardeep Jhund, PhD6; John Petrie, PhD6; 
Naveed Sattar, PhD6; Colin Fischbacher, MD2; Soren Lund Kristensen, PhD7;  
John McMurray PhD6; Helen M. Colhoun, PhD3*; Sarah Wild PhD3* 
*Joint last authors 
 
1Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK; 2NHS National 
Services Scotland, Edinburgh, UK; 3Usher Institute, University of Edinburgh, Edinburgh, UK; 
4School of Medicine, University of Dundee, Dundee, UK; 5MRC Institute of Genetics & 
Molecular Medicine, University of Edinburgh, Edinburgh, UK; 6Institute of Cardiovascular and 
Medical Sciences, University of Glasgow, Glasgow, UK; 7Bispebjerg Hospital, Copenhagen 
University, Copenhagen, Denmark 
 
Address for Correspondence: 
David McAllister, MD 
University of Glasgow 
Institute of Health and Wellbeing 
1 Lilybank Gardens 
University of Glasgow, G12 8RZ 
Tel: 0141 330 1663 
Email: david.mcallister@glasgow.ac.uk 
Twitter handle: @dvdmcllstr  
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.118.034986 
2 
Abstract 
 
Background—Recent clinical trials of new glucose-lowering treatments have drawn attention to 
the importance of hospitalisation for heart failure as a complication of diabetes. However, the 
epidemiology is not well described, particularly for type 1 diabetes. We examined the incidence 
and case-fatality of heart failure hospitalisations in the entire population aged 30 and older 
resident in Scotland during 2004 to 2013. 
Methods—Date and type of diabetes diagnosis were linked to heart failure hospitalisations and 
deaths using the national Scottish registers. Incidence rates and case-fatality were estimated in 
regression models (quasi-Poisson and logistic regression respectively). All estimates are adjusted 
for age, sex, socio-economic status and calendar-year. 
Results—Over the 10-year period of the study, among 3.25 million people there were 91,429, 
22,959 and 1,313 incident heart failure events among those without diabetes, with type 2, and 
type 1 diabetes respectively. The crude incidence rates of heart failure hospitalisation were 
therefore 2.4, 12.4 and 5.6 per 1000 person-years for these three groups. Heart failure 
hospitalisation incidence was higher in people with diabetes, regardless of type, than in people 
without. Relative differences were smallest for older men, in whom the difference was 
nonetheless large (men aged 80, rate ratio 1.78; 95% CI 1.45 to 2.19). Rates declined similarly, 
by 0.2% per calendar-year, in people with type 2 diabetes and without diabetes. Rates fell faster, 
however, in those with type 1 diabetes (2.2% per calendar-year, RR for type 1/calendar-year 
interaction 0.978; 95% CI 0.959 to 0.998).30-day case-fatality was similar among people with 
type 2 diabetes and without diabetes, but was higher in type 1 diabetes for men (OR 0.96; 95% 
CI 0.95 to 0.96) and women (OR 0.98; 95% CI 0.97 to 0.98). Case-fatality declined over time for 
all groups (3.3% per calendar-year, OR per calendar-year 0.967; 95% CI 0.961 to 0.973). 
Conclusions—Despite falling incidence, particularly in type 1 diabetes, heart failure remains 
around 2-fold higher than in people without diabetes, with higher case-fatality in those with type 
1 diabetes. These findings support the view that heart failure is an under-recognised and 
important complication in diabetes, particularly for type 1 disease. 
 
Key Words: Epidemiology; Electronic Health Records; Registries; Diabetes Mellitus; Type 1; 
Diabetes Mellitus; Type 2; Incidence; mortality. 
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Clinical Perspective 
 
What is new 
• Heart failure incidence has fallen over time for people with and without diabetes, but is 
around 2 times higher in people with diabetes than people without diabetes 
• Heart failure case-fatality is higher in people with type 1 diabetes 
• Duration of diabetes and glycated haemoglobin was associated with increased risk of 
heart failure in type 1 and type 2 diabetes 
 
What are the clinical implications? 
• Clinicians should be aware of the importance of heart failure in diabetes, especially in 
type 1 diabetes, where this risk is under-appreciated 
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Introduction 
Recent clinical trials of new glucose-lowering treatments have drawn attention to the importance 
of hospitalisation for heart failure as a complication of diabetes.1–4 However, little is known 
about the epidemiology of heart failure in unselected individuals with type 2 diabetes, and even 
less about those with type 1 diabetes. 
 We have examined the incidence of heart failure for an entire country, and how this has 
changed over time. All residents in Scotland receive care from the National Health Service 
which is free at the point of contact. All diabetes-related community (primary care) and hospital 
outpatient encounters in Scotland are recorded in a centrally-accessible database and these are 
linked to national hospitalisation and mortality records. Given the prognostic import of 
developing heart failure, we have also investigated the case-fatality related to incident heart 
failure hospitalisation and how this has changed over time. 
 Specifically, we examined the incidence rate for heart failure hospitalisation and 30-day 
case-fatality following heart failure hospitalisation over a 10-year period from January 2004 to 
December 2013 among people with diabetes (type 1 and type 2). 
 
Methods 
Access to data and methods 
The data, analytic methods, and study materials will not be made available to other researchers 
for purposes of reproducing the results or replicating the procedure. However, individual-level 
data are available via application to NHS Information Services Scotland,5 aggregate data are 
provided in the supplementary appendix (Supplemental Tables 1 and 2), and analysis code has 
been posted online.6 
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Datasets 
We used data from the population-based Scottish diabetes register linked to national 
hospitalisation and death records. The Scottish diabetes register is derived from primary and 
secondary care records for people with diabetes diagnosed in normal clinical practice using 
blood glucose measurements and/or HbA1c with coverage of >99% since 2004,7 the start of the 
study period. Anyone alive in Scotland aged 30 and older at any time from 2004 to 2013 was 
included in the analyses. 
Definition of heart failure 
Heart failure was identified from the first mention in any position (primary or secondary 
diagnoses) in hospital in-patient records using codes from the ninth (ICD-9) and tenth (ICD-10) 
International Classification of Diseases revisions (402, 402, 402.1, 402.2, 402.4, 402.6, 402.9, 
425.5, 428, 428, 428.1, 428.9 and I11.0, I13.0, I13.2, I42.6, I50.0, I50.1, I50.9 respectively). 
Outpatient attendances with heart failure are not recorded in the Scottish national healthcare 
database, nor in the Scottish diabetes register. 
Diabetes status and diagnosis date 
Date and type of diabetes were obtained from the diabetes register based on the clinician-
recorded date of diagnosis. Diabetes status was defined as type 2 diabetes, type 1 diabetes and no 
diabetes. 
Covariates 
Age at first heart failure hospitalisation and sex were identified from hospital admission and 
mortality records. Socio-economic status was assessed via an area-based measure of deprivation 
which is assigned to residents of Scotland on the basis of where they live using the Scottish 
Index of Multiple Deprivation (SIMD).8 SIMD 2009 combines 31 indicators across seven 
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domains: income—employment, health, education, housing, geographic access, and crime. The 
index is generated from a weighted sum of the seven domain scores for each area defined by 
postcodes (zip codes) which contain a median of 769 people. SIMD data were missing for 
approximately 1% of hospital admissions or death records and these records were excluded from 
the analysis. 
Clinical risk factors 
As an additional analysis, in order to explore the association between demographic and clinical 
risk factors and subsequent risk of heart failure admissions, we also identified a closed cohort 
from the Scottish Diabetes Register. All patients in this cohort had been diagnosed with type 1 or 
type 2 diabetes on or prior to the 1st of October 2013 and had not had a heart failure admission in 
the 10-years prior to this date. Follow-up data was available for three years. 
 Heart failure in the closed cohort was defined as per the main analysis. However, the 
clinician-recorded diabetes type was corrected through the use of additional clinical information 
(eg medication use) as described in a previous publication.9 
 For this cohort, baseline characteristics such as glycated haemoglobin, body mass index, 
duration of diabetes, blood pressure, and retinopathy were also obtained from the diabetes 
register, taking the mean (or mode) of all measures not more than 3-years prior to the start date. 
Data on current prescriptions for selected drug classes (Supplemental Table 3) was also obtained, 
as was data on previous stroke and myocardial infarction within the previous ten years. 
Statistical analysis 
Hospitalisations and deaths 
Using the population-based Scottish diabetes register, linked to national hospitalisation and death 
records, heart failure hospitalisations from January 1st 2004 (or the date at which each person 
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was diagnosed with diabetes, if this occurred during the study period) to December 31st 2013 
were identified for people with diabetes aged 20-89 years. Heart failure hospitalisations were 
defined as incident if these were the first to occur on or after January 2004 where no previous 
heart failure hospitalisation had been recorded during the preceding 10-years (Supplemental 
Figure 1). As with our previous analyses we used a fixed period to define incident cases to avoid 
bias from non-observation of prevalent cases.10 This analysis was replicated using the entire 
national hospitalisation and death record to identify heart failure hospitalisations for the general 
adult population. Incident hospitalisations were summed by calendar-year, age, sex, deprivation 
decile and, for the diabetes dataset, diabetes type. Within the levels of these stratifying variables, 
the number of incident heart failure hospitalisations in people without diabetes was derived by 
subtracting the diabetes heart failure hospitalisations from the general population heart failure 
hospitalisations. 
 Case-fatality was examined at 30-days, defined as the proportion of patients who died 
from any cause within 30 days of any heart failure hospitalisation. Both in-hospital and out of 
hospital deaths were included. 
Person-time 
As for hospitalisations, person-time for people with diabetes was estimated using the linked 
diabetes register, hospitalisation and death data. Each individual’s person-time was estimated as 
the number of days from the start of the study period (or date at which each person was 
diagnosed with diabetes, if this occurred during the study period) to the date of the incident heart 
failure hospitalisation, death or censoring at December 31st, 2013 (Supplemental Tables 4 and 5). 
This was summed by diabetes type, calendar-year, age, sex, and deprivation decile. Mid-year 
population estimates for the general population in Scotland, stratified by age, sex and deprivation 
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were obtained from National Records of Scotland. For people without diabetes, person-time not 
at risk (due to prevalent or incident heart failure events) was also summed by the same stratifying 
variables. Within the levels of these stratifying variables, person-time for people with no diabetes 
was obtained by subtracting the diabetes person-time from the mid-year estimates population 
estimates. 
Modelling 
Heart failure incidence rates were estimated by age, sex, deprivation, calendar-year and diabetes 
status. Confidence intervals for the rate ratios and rate differences were obtained as per 
Rothman.11 
 For the main analysis, regression models were fit using non-parametric smooth terms 
(penalized thin plate regression splines) and interaction terms to allow for non-linearity and 
heterogeneity respectively. We used regression in preference to stratification to avoid 
categorising continuous variables, which can result in unstable estimates if a stratum is too small, 
and loss of information if a stratum is too heterogeneous. 
 Interactions are reported on the same scale as the main effects as the RR or OR, since this 
can be interpreted as the relative difference in the magnitude of an association per one-unit 
change in the interacting variable. 
 For incidence rates, generalized linear models were used with a log-link and Poisson 
error distribution, using a scaling factor (quasi-Poisson) to allow for overdispersion. Age in years 
was divided by ten so that each increment was a decade (eg age 44 was transformed to 4.4). 
Deprivation deciles were treated as a deprivation score ranging from 1 to 10, which was divided 
by 5 such that each increment was a 5-point increment. Terms were included for main effects in 
all models regardless of significance or magnitude of effect. The large and heterogeneous study 
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population with a large number of events allowed us to investigate whether the magnitude of risk 
associated with diabetes varied by biologically plausible and clinically relevant variables on the 
basis of prior knowledge of diabetes and heart failure. Interaction terms (between 2 or more of 
age, sex, deprivation and diabetes status) were retained if the exponentiated coefficient (on the 
transformed scale) was ≥ 1.05 or ≤ 0.95. However, for interactions with calendar-year, all 
statistically significant interactions (at P <0.05) were included in the final models. Using the 
same covariates, generalized linear models with a logit-link and binomial error distribution were 
used to model both heart failure prevalence and case-fatality. 
 In additional analyses these models were repeated after excluding patients with a 
previous admission for ischaemic heart disease (ICD-9 410-414 or ICD-10 I20-25), and in 
separate sensitivity analyses after adding additional ICD-10 codes (I42.0, I42.7, I42.8, I42.9) for 
cardiomyopathy, and after restricting the analysis to admissions where heart failure was the 
primary diagnosis (recorded in the first of six possible diagnostic positions). 
 For the analysis of the association between the 3-year risk (odds) of heart failure and 
clinical and demographic characteristics in the closed cohort, we used logistic regression models. 
Covariate missingness was addressed using multiple imputation (supplementary appendix). We 
fitted models for type 1 and type 2 diabetes, and a third model which included 
covariate/diabetes-type interaction terms to compare risk factor associations between type 1 and 
type 2 diabetes. Multiple imputation was used for missing data (Supplemental Table 6). 
 The association between heart failure and drug prescription was not modelled due to the 
high likelihood of confounding by indication. However, we did compare the odds of 
cardiovascular medication prescription in people with type 2 versus type 1 diabetes. Each drug 
class was modelled unadjusted, adjusting for age and sex, and for the risk of heart failure (on the 
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logit scale) according to each person’s baseline characteristics. The latter was derived from the 
model of 3-year risk in the closed cohort described above. 
 SPSS was used to extract the administrative data and R version 3.4.3 (Vienna, Austria) 
was used for the statistical analyses. 
 Approval for the creation and analysis of the linked dataset containing no person-
identifying information was obtained from the Scottish Care Information - Diabetes 
Collaboration (SCI-DC) steering committee, the Scottish multi-centre research ethics committee 
(reference number 11/AL/0225), the Privacy Advisory Committee of NHS National Services 
Scotland and Caldicott guardians. 
 
Results 
This study included the entire Scottish population who were aged 30 or older at any time 
between 2004 to 2013. In 2004, this comprised 3,066,253 people without a diagnosis of diabetes, 
136,042 with a diagnosis of type 2 diabetes and 18,240 with a diagnosis of type 1 diabetes. Of 
these 1,642,022 (53.6%), 63,086 (46.4%) and 8,141 (44.6%), respectively, were women and the 
mean (and standard deviation [SD]) ages were 52.9 (15.3), 65.0 (12.2) and 50.0 (14.1) years, 
respectively. SIMD was similar across the groups with mean (SD) deprivation scores of 5.5 
(2.9), 5.9 (2.8) and 5.6 (2.8), respectively.  
Incidence of heart failure hospitalisation 
28,681 people without diabetes, 3,480 with type 2 diabetes, and 382 with type 1 diabetes were 
excluded because of a previous heart failure hospitalisation (Supplemental Figures 2 and 3, 
Supplemental Table 7). Over the 10-year period of the study, among the 3.25 million people 
remaining there was 91,429, 22,959 and 1,313 incident heart failure events (during 38,112,739.9, 
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1,855,281.8 and 235,924.2 person-years) among those without diabetes, with type 2 diabetes, 
and with type 1 diabetes, respectively. 
 Heart failure incident hospitalisation estimated rates from Poisson regression models 
adjusting for age, sex and deprivation are shown in Figure 1 (and additionally in Supplemental 
Figures 4 and 5 and in Supplemental Table 8). For illustration, age-sex stratified rates for 2013 
are shown in Table 1. Rates varied markedly with age and differed according to sex and whether 
or not diabetes was present. 
 Overall, the rate of incident heart failure hospitalisation rose steeply with age, was 
somewhat higher in men than in women and was higher in individuals with diabetes than in those 
without this diagnosis. Incident heart failure hospitalization was also higher in people with type 1 
compared to type 2 diabetes. 
 We found the relative risk of diabetes-related heart failure hospitalization (as indicated by 
the rate ratio) was highest in younger people and higher in women than men (Figure 1 and Table 
1). However, as the absolute rate of incident heart failure was highest in older individuals, the 
greatest difference in absolute rates were also seen in these groups, and not in younger people 
and women (Figure 1). 
Time trends in incident heart failure hospitalisation 
Across the period studied, the rate of incident heart failure hospitalisation fell slightly, at around 
0.2% per calendar-year (RR per calendar-year 0.998; 95% CI 0.991 to 1.005). 
 In models adjusting for age, sex and deprivation, the rate of decline was slightly steeper 
in older individuals. The rate of decline was 0.5% per calendar-year faster per ten-year increment 
in age (RR for interaction 0.995; 95% CI 0.992 to 0.998), and was similar in men and women 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.118.034986 
12 
(RR for interaction 1.006; 95% CI 0.998 to 1.014), and according to deprivation (RR for 
interaction (per 5-point increment in deprivation score) 0.996; 95% CI 0.989 to 1.003) 
 From the same model, trends in heart failure incidence rates in people with type 2 
diabetes were similar to those in individuals without diabetes over a ten-year period from 2004 
(Figure 2, Supplemental Tables 9 and 10). However, there was some evidence of a more rapid 
decline in people with type 1 diabetes, where the decrease was 2.2% per calendar-year faster 
than in people without diabetes. 
 An interactive version of Figure 2, where diabetes type and sex-specific temporal trends 
can be shown for patients of any age or with any level of socio-economic deprivation, is 
available at https://ihwph-hehta.shinyapps.io/dm_hf_fig2/. 
 Notwithstanding any temporal decrease in absolute rates, the rate ratios for heart failure 
hospitalization remained large throughout the study period for both types of diabetes. For 
example, in 2013 the rate ratios in people with type 2 diabetes, compared to those with no 
diabetes, were 5.81 (95% CI 4.91 to 6.86) and 3.55 (95% CI 2.99 to 4.21) for 50-year-old women 
and men, respectively. 
Case-fatality of incident heart failure hospitalisation 
Over the period of the study, 14.2% (16406/115701) of people admitted to hospital with heart 
failure died within 30-days of admission. 
 30-day case-fatality results obtained from logistic regression models adjusting for age, 
sex and deprivation are shown in Figure 3 (see supplementary appendix for model coefficients, 
including interactions). For illustration, age-sex stratified case-fatality is shown in Table 2. Case-
fatality varied markedly with age and differed according to sex and whether or not type 1 
diabetes was present. It was higher in women than in men and in older people than in younger 
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people. However, it was similar in people with type 2 diabetes and in people without diabetes, 
for men the odds ratio (OR) was 0.96 (95% CI 0.95 to 0.96) and for women the OR was 0.98 
(95% CI 0.97 to 0.98). 
 However, case-fatality was higher among people with type 1 diabetes compared to people 
without diabetes; the difference was larger for men (OR 1.91; 95% CI 1.68 to 2.18) than for 
women (OR 1.31; 95% CI 1.05 to 1.65). 
 Trends in case-fatality were also modelled adjusting for age, sex, deprivation, calendar-
year and type of diabetes (Figure 4, Supplemental Tables 11 and 12). The rate of decline was 
around 3.3% per calendar-year (OR per calendar-year 0.967; 95% CI 0.961 to 0.974) in people 
without diabetes. There was no evidence of a steeper decline in people with type 1 diabetes (OR 
for calendar-year/type 2 interaction 1.011; 95% CI 0.959 to 1.065) or type 2 diabetes (OR for 
calendar-year/type 2 interaction 0.994; 95% CI 0.979 to 1.009.) 
Incidence of heart failure hospitalisation without previous ischaemic heart disease  
Incident heart failure hospitalisation was lower in people who had never had a previous 
admission for ischaemic heart disease admission (ICD-9 410-414 or ICD-10 I20-25), with rates 
per 1,000 person-years (py) of 1.7 (65,657 events/38,117,663.1 py), 9.2 (17,175 events/ 
1,867,390.1 py) and 3.6 ( 841 events/ 236,843.7 py) for the no-diabetes, type 2 diabetes and type 
1 diabetes groups respectively. Nevertheless, the rate ratios for both type 1 and type 2 diabetes in 
this group (Figures 5, Supplemental Figures 6 and 7, and Supplemental Tables 13-16) were 
similar to those in the whole cohort (Figure 1). 
 by guest on July 5, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.118.034986 
14 
Risk factors for heart failure in people with diabetes 
28,8208 people with type 2 diabetes and 26,189 with type 1 had not had a previous hospital 
admission with heart failure on October 1st 2013. In this cohort, over 3-years of follow-up the 
risk of heart failure was 6752 (2.3%) and 231 (0.9%) for type 2 and type 1 diabetes respectively. 
Age, sex, body mass index, estimated glomerular filtration rate, smoking, previous ischaemic 
heart disease and stroke all predicted an increased risk of heart failure, although no associations 
were found for systolic blood pressure, total cholesterol or HDL cholesterol (Table 3). After 
adjusting for conventional risk factors, longer duration of diabetes and higher concentrations of 
HbA1c also predicted heart failure risk. Of note, there was no evidence that any of the predictors 
of heart failure differed between type 1 and type 2 diabetes. 
 People with type 2 diabetes were more likely than those with type 1 diabetes to have a 
current prescription for a range of cardiovascular drugs (Table 4). Across all drug-classes 
examined, compared to people with type 1 diabetes, those with type 2 diabetes were more likely 
to have been prescribed cardiovascular medications. For loop diuretics and antiplatelets the risk 
was not higher after adjusting for age and sex (OR 0.87; 95% CI 0.82-0.93 and OR 1.03; 95% CI 
0.99-1.07 respectively. However, for the remaining cardiovascular drug classes (including lipid 
lowering drugs, drugs acting on the renin-angiotensin system and calcium channel blockers) 
higher prescription levels in type 2 diabetes persisted on adjusting for age and sex, and on 
adjusting for the predicted risk of heart failure (Table 4). 
Sensitivity analyses 
On restricting incident heart failure admissions to those where heart failure was the primary 
diagnosis, the heart failure incidence rates were around half of those reported for any incident 
admission, with rates per 1,000 person-years (py) of 0.9 (34,893 events/38,080,361.9 py), 6.1 
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(11,551 events/ 1,885,715.8 py) and 2.7 (635 events/ 237,683.5 py) for the no-diabetes, type 2 
diabetes and type 1 diabetes groups respectively. Nonetheless, compared to the main analysis 
(Figure 1, Supplemental Figures 4 and 5 and Supplemental Table 7) similar associations were 
found (Supplemental Figures 8 and 9 and Supplemental Tables 17-19). On adding 
cardiomyopathy codes (I42.0, I42.7, I42.8, I42.9) to the heart failure definition used in the main 
analysis, similar results were also found; this was true for the absolute incident rates and case-
fatality, and the rate ratios and odds ratio comparing the three groups (type 1, type 2 and no 
diabetes). 
 On comparing the clinician-recorded and corrected clinician-recorded definitions of 
diabetes type in the closed cohort, similar associations between type of diabetes and 3-year risk 
of heart failure were found; adjusting for age, sex and deprivation, the odds ratios were 1.24 
(95% CI 1.09-1.40) and OR 1.21 (95% CI 1.05-1.38) respectively. 
 
Discussion 
We documented the rate of incident heart failure hospitalisations in a large and complete national 
dataset which included over 250,000 people with diabetes among a population of more than 3.25 
million people aged ≥30 years, in whom there were more than 115,000 first hospitalisations for 
heart failure. 
 We examined trends in these rates, and the associated 30-day case-fatality, over a ten-
year period (2004-2013). Importantly, we reported these rates and trends separately for people 
with type 1 as and type 2 diabetes. 
 We found that the age and sex adjusted rates of incident heart failure hospitalisation were 
around 2-fold higher in people with diabetes, regardless of type, compared to those without 
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diabetes. In all groups, there was a decline in incidence rate of around 2% over the decade 
studied, with a slightly greater rate of decline in people with type 1 diabetes than in the other 
groups studied. 
 In terms of trends, heart failure incident hospitalisation appears to be falling more quickly 
over time (both in absolute and proportional terms) in people with type 1 diabetes, compared to 
people with type 2 diabetes and to people without diabetes. The difference was moderate; having 
adjusted for age, sex and deprivation the decline was faster in those with type 1 diabetes (2.1% 
per year versus 0.2% per year). We are not aware that this finding has been reported previously, 
but it is consistent with an observation from the Swedish registry that the rate ratio for type 1 
diabetes and incident heart failure was larger in the 1998 to 2004 period than in the 2005 to 2011 
period.2 
 We also found that the relative difference in heart failure incidence between people 
without diabetes and those with type 1 or type 2 diabetes was larger for younger people and for 
women than for older people and men. This is consistent with previous reports.1–3 It is important 
to note, however, that because of the higher overall rates in men and older people, the absolute 
differences in heart failure incidence were larger in these groups. Therefore, from the perspective 
of the individual patient, the impact of diabetes on heart failure risk is greater at older ages and in 
men. Indeed, the absolute difference in one-year risk of heart failure admission in 80-year old 
men (the group with the smallest relative difference) with and without diabetes was 2.5%. For 
the same comparison, but in 40-year old women, the difference was less than 0.5%. 
Unlike incidence, for case-fatality the relationship with diabetes depended on the type of 
diabetes. Case-fatality was similar among people with type 2 diabetes compared those without 
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diabetes. However, among people with type 1 diabetes, case-fatality was 1.3-fold higher in 
women, and 1.9-fold higher in men. 
 Women therefore have a 2-fold higher heart failure incidence and a 1.3-fold higher case-
fatality. In combination, this means that compared to women without diabetes, women with type 
1 diabetes have around a 2.5-fold higher risk of having an incident heart failure admission which 
results in death within 30-days. For the equivalent comparison in men, there is almost a 4-fold 
difference in risk. 
 Elevated incidence rates for heart failure admission among people with type 2 diabetes 
have been reported previously. One study using the Clinical Practice Research Database (CPRD) 
used primary care records to define heart failure and type 2 diabetes. The authors identified 
34,198 people with type 2 diabetes from 1998 to 2010. Among women over the age of 60 with 
and without type 2 diabetes, they found a relative difference (hazard ratio) of 1.50.3 We obtained 
a similar relative difference (rate ratio) of 2.12 (95% CI 2.06-2.17). For men over 60, the 
comparable figures were 1.43 and 1.93 (95% CI 1.88-1.98) respectively. The fact that we 
included only hospitalisations, and not primary care attendances, may account for the slightly 
stronger associations we report. 
 In the international REACH registry, there was also an elevated risk of heart failure 
hospitalisation among the 19,699 people with diabetes (type unspecified) compared to people 
without diabetes.1 However, the magnitude of the association in this cohort, which mainly 
included people with established atherothrombotic disease or risk factors for atherothrombosis, 
was weaker than we found at 1.33-fold. In sensitivity analyses excluding any patient with a 
previous ischaemic heart disease admission, we continued to observe an approximately 2-fold 
association. However, we did not have any measures of stable coronary disease. As such, one 
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explanation for the stronger association we observed is that the increased heart failure risk in 
diabetes is partly related explained through increased risk of atheromatous disease. 
 Previous studies examining case-fatality following heart failure admissions among people 
with type 2 diabetes have been equivocal. One multi-centre register study found no difference in 
in-hospital mortality among people with diabetes compared to those without (OR 1.00; 95% CI 
0.88-1.14).12 Similarly, in a study in the Scottish population comparing incident heart failure 
admissions from 1986-2003, the age-sex adjusted 30-day case-fatality following heart failure 
admission was lower in people with diabetes than in those without diabetes (for example in men 
aged 65 to 74 the OR was 0.82; 95% CI 0.73-0.93), although case-fatality at one-year was 
higher.13 Neither study, however, included data on diabetes type. Since the majority of people 
with diabetes have type 2 diabetes, these reports are consistent with our own finding that people 
with type 2 diabetes did not have a higher case-fatality than individuals without diabetes. 
 Fewer studies have examined heart failure as a complication of type 1 diabetes. The 
largest, which was a population-based study from Sweden, and which updates and extends a 
previous report from the same diabetes registry,14 reported a rate of incident heart failure 
hospitalisation of 6.7 per 1,000 person-years in people with type 1 diabetes compared to 4.0 per 
1,000 person-years in individuals without diabetes, similar to the difference we observed.2 
However, those investigators did not examine trends over time or case-fatality. Indeed, ours is 
the first population-based study of which we are aware to compare case-fatality following heart 
failure admissions in people with and without type 1 diabetes, and we are not aware that the high 
case-fatality in patients with type 1 diabetes has been reported previously. 
 The mechanisms underlying this difference in case-fatality are unknown, and mechanistic 
studies are needed. Indeed, excepting coronary artery atherosclerosis, the mechanisms 
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underlying the relationship between diabetes and heart failure are not well understood, and 
whether or not diabetic cardiomyopathy represents a distinct entity or not remains 
controversial.15–17 Notwithstanding the mechanisms, however, the increased case-fatality 
provides additional support for the view that heart failure is an under-recognised and important 
complication in type 1 diabetes.18 
 Time-trends in case-fatality were similar across groups. For people with and without 
diabetes, regardless of type, we found that case-fatality fell by around 3% per-year. We were 
unable to identify any previous study which compared heart failure admission case-fatality trends 
among people with and without diabetes. Nonetheless, similar trends have been reported in 
unselected patients, and in people with type 2 diabetes. In terms of the former, a study using the 
Swedish national hospital discharge register, which included 13.6% of people with type 2 
diabetes, found a decline of approximately 4% per-year (hazard ratio 0.96 per year during the 
five-year period from 1987 to 2006).19 Also, trends following heart failure admissions were 
examined for people with type 2 diabetes in a subset of the US National Inpatient Sample 
mortality (defined using administrative data - ICD-9-CM codes 250.0 to 250.9 with a fifth digit 
of 0 or 2). In models adjusting for age and sex, case-fatality fell by approximately 5% per year 
from 2000 to 2010.20 This is consistent, therefore with our findings. 
 In the general adult population, a number of risk factors such as age, sex, deprivation, 
smoking, obesity, hypertension, cholesterol and previous cardiovascular disease are known to 
predict heart failure.21 Lind et al also showed that, among people with type 1 diabetes, smoking, 
systolic blood pressure, high body mass index, duration of diabetes and HbA1c were associated 
with increased heart failure incidence.14 We obtained similar findings for the association between 
these risk factors and the 3-year risk of heart failure among people with type 1 diabetes. We have 
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also been able to show that very similar associations (both in terms of magnitude and direction) 
are evident for people with type 2 as well as type 1 diabetes. 
 We also found that people with type 1 diabetes were less commonly prescribed drugs 
known to reduce the risk of heart failure, (whether directly or through reducing the risk of heart 
disease); this included antihypertensives, drugs acting on the renin-angiotensin system and lipid 
lowering drugs.22 Importantly, these differences were still found after taking into account the fact 
that people with type 2 diabetes are older, and even after adjusting for each patient’s predicted 
risk of heart failure (based on their baseline characteristics). Considerable caution is needed in 
interpreting this finding, as the clinical risk factors (blood pressure, smoking etc) used to adjust 
for baseline risk were obtained as part of routine clinical care, not in a prospective study, and 
were not available for some patients. Nonetheless, this observation does raise the possibility that, 
even where the heart failure risk is similar, people with type 1 diabetes may be less likely than 
people with type 2 diabetes to receive preventative drug therapy. 
 The strengths of our study include the very large population-based nature of the 
electronic record of diagnosed diabetes that captures data for >99% of the population of 
Scotland, information on the type of diabetes, and the availability of linkage to quality-assured 
hospital admission and mortality data for the whole population.23 A limitation is that heart failure 
events insufficiently severe to require admission to hospital were not captured as we did not have 
access to primary care data.  
 However, we have previously shown via review by two independent clinicians (a 
generalist and cardiologist) that heart failure admissions in the Scottish hospitalisation database 
are reliably recorded.24 Moreover, similar associations were found in a sensitivity analysis which 
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restricted the definition of heart failure to admission where this was coded in the first diagnostic 
position. 
 Secondly, while the data were of high quality some misclassification as a result of 
diagnostic uncertainty is likely to have occurred. In particular, some people with type 1 diabetes 
will have been classified as type 2 diabetes, and vice versa. However, there is no reason to 
suppose that this misclassification will have been differential by outcome, and it is therefore 
likely to have attenuated any observed differences between type 1 and type 2 diabetes. Indeed, in 
the cohort restricted to patients with diabetes in 2013, the use of a more precise definition of 
diabetes type did not importantly affect the estimated 3-year risk of diabetes. A further limitation 
is that we did not have accurate data on race or ethnicity, and so cannot comment on whether 
associations between diabetes and heart failure incidence differ by these variables. 
 Finally, we did not have access to sufficient data on left ventricular function to comment 
on the relative contribution of reduced and preserved ejection fraction heart failure on the 
differences between people with and without diabetes. 
Conclusion 
Despite falling incidence rates, particularly in type 1 diabetes, heart failure remains around 2-
fold higher than in people without diabetes, with case-fatality also being higher in people with 
type 1 diabetes. Those with type 1 diabetes also received fewer preventative cardiovascular 
medications. These findings provide additional support for the view that heart failure is an under-
recognised and important complication in diabetes, particularly among people with type 1 
diabetes. 
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Table 1. Incidence of heart failure admissions stratified by age and sex 
 
Age Sex  No diabetes Type 1 diabetes Type 2 diabetes 
20-29 Men Rate 0.07 (26/354,377) 0.36 (1/2,748) 0 (0/386) 
  Rate ratio - 4.96 ( 0.67-36.55)  
  Rate diff. - 0.29 (-0.42- 1.00) -0.07 (-0.10–0.05) 
 Women Rate 0.08 (27/359,972) 0.46 (1/2,162) 2.18 (1/459) 
  Rate ratio - 6.17 ( 0.84-45.38) 29.07 ( 3.95-213.94) 
  Rate diff. - 0.39 (-0.52- 1.29) 2.11 (-2.17- 6.38) 
30-49 Men Rate 0.45 (309/679,479) 1.11 (7/6,304) 1.61 (23/14,260) 
  Rate ratio - 2.44 (1.15-5.17) 3.55 (2.32-5.42) 
  Rate diff. - 0.66 (-0.17- 1.48) 1.16 (0.50-1.82) 
 Women Rate 0.2 (144/721,321) 1.54 (7/4,555) 1.5 (15/9,984) 
  Rate ratio - 7.70 ( 3.61-16.44) 7.53 ( 4.42-12.81) 
  Rate diff. - 1.34 (0.20-2.48) 1.30 (0.54-2.06) 
50-69 Men Rate 2.31 (1360/587,720) 8.26 (38/4,599) 6.88 (452/65,712) 
  Rate ratio - 3.57 (2.59-4.93) 2.97 (2.67-3.31) 
  Rate diff. - 5.95 (3.32-8.58) 4.56 (3.92-5.21) 
 Women Rate 1.09 (702/645,356) 6.23 (21/3,371) 5.25 (231/43,998) 
  Rate ratio - 5.73 (3.71-8.84) 4.83 (4.16-5.60) 
  Rate diff. - 5.14 (2.48-7.81) 4.16 (3.48-4.84) 
70-89 Men Rate 12.68 (2832/223,396) 31.4 (27/860) 22.21 (994/44,756) 
  Rate ratio - 2.48 (1.70-3.62) 1.75 (1.63-1.88) 
  Rate diff. - 18.72 ( 6.87-30.57) 9.53 ( 8.07-10.99) 
 Women Rate 10.26 (3361/327,652) 30.65 (31/1,011) 19.75 (914/46,277) 
  Rate ratio - 2.99 (2.10-4.26) 1.93 (1.79-2.07) 
  Rate diff. - 20.39 ( 9.60-31.19) 9.49 ( 8.17-10.82) 
Rates and rate differences are per 1,000 person year, rate ratios and rate differences are reported with 95% 
confidence intervals. 
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Table 2. 30-day case-fatality of incident heart failure hospitalisation, by age and sex 
 
Age Sex No diabetes Type 1 diabetes Type 2 diabetes 
20-39 Men 4.0% (8/199) 10.0% (1/10) 0.0% (0/4) 
 Women 4.6% (6/130) 0.0% (0/7) 0.0% (0/5) 
30-49 Men 4.4% (131/2953) 9.3% (10/107) 3.1% (8/258) 
 Women 7.8% (97/1248) 8.8% (6/68) 6.2% (8/129) 
50-69 Men 6.9% (974/14175) 13.6% (43/316) 7.3% (305/4151) 
 Women 10.0% (721/7242) 10.6% (25/236) 9.4% (196/2082) 
70-89 Men 16.5% (4795/29013) 23.0% (63/274) 14.6% (1216/8318) 
 Women 17.7% (6462/36469) 18.3% (54/295) 15.9% (1277/8012) 
All Men 12.7% (5908/46340) 16.5% (117/707) 12.0% (1529/12731) 
 Women 16.2% (7286/45089) 14.0% (85/606) 14.5% (1481/10228) 
Case-fatality shown as percentages (deaths/admissions). 
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Table 3. Risk factors for heart failure in people with diabetes. Summary statistics, association with incident heart failure hospitalisation 
within three years and comparison of association in type 1 versus type 2 diabetes  
 
Risk factor Summary statistics Heart failure  
risk factors stratified 
Heart failure  
risk factors comparison  
Type 1 Type 2 Type 1 Type 2 Type 1/Type 2 P-value 
N 26189 288208     
Age (years) 45 (15) 65 (13) 1.85 (1.57-2.19) 1.99 (1.91-2.07) 0.93 (0.78-1.11) 0.42 
Male 14907 (56.9%) 162029 (56.2%) 1.05 (0.79-1.40) 1.16 (1.09-1.22) 0.91 (0.68-1.22) 0.52 
Deprivation (Deciles) 5 (3 to 8) 5 (3 to 7) 1.14 (0.99-1.32) 1.10 (1.06-1.12) 1.04 (0.90-1.20) 0.57 
Body mass index (kg/m2) 26 (24 to 30) 31 (28 to 35) 1.22 (1.04-1.45) 1.26 (1.23-1.30) 0.97 (0.82-1.15) 0.74 
Never smoker 13047 (54.7%) 113952 (43.6%) 1 1 1 - 
Ex-smoker 4510 (18.9%) 92826 (35.5%) 1.91 (1.38-2.63) 1.22 (1.15-1.30) 1.56 (1.12-2.16) 0.008 
Current smoker 6297 (26.4%) 54874 (21%) 2.04 (1.42-2.93) 1.59 (1.48-1.71) 1.28 (0.88-1.86) 0.20 
Systolic blood pressure (mmHg) 130 (13) 136 (13) 1.06 (0.93-1.20) 1.08 (1.05-1.11) 0.98 (0.86-1.11) 0.73 
Diastolic blood pressure (mmHg) 75 (8) 77 (8) - - - - 
Total cholesterol (mg/dL) 4.7 (1) 4.4 (1) 1.30 (1.15-1.48) 0.99 (0.96-1.02) 1.32 (1.16-1.51) <0.001 
LDL cholesterol (mg/dL) 2.5 (0.8) 2.3 (0.9) - - - - 
HDL cholesterol (mg/dL) 1.5 (0.4) 1.2 (0.3) 0.90 (0.79-1.02) 1.00 (0.97-1.03) 0.90 (0.79-1.02) 0.10 
HbA1c (mmol/mol) 71 (62 to 83) 56 (48 to 67) 1.32 (1.16-1.51) 1.17 (1.13-1.20) 1.13 (0.99-1.29) 0.06 
Estimated glomerular filtration rate (ml/min) 98 (83 to 110) 81 (65 to 93) 0.65 (0.56-0.75) 0.72 (0.70-0.74) 0.90 (0.77-1.05) 0.17 
Previous stroke 275 (29.3%) 7278 (26.7%) 1.93 (1.09-3.40) 1.36 (1.21-1.52) 1.42 (0.80-2.53) 0.24 
Previous myocardial infarction 585 (62.4%) 18224 (66.7%) 1.60 (1.03-2.49) 1.68 (1.56-1.80) 0.96 (0.61-1.50) 0.84 
Duration of diabetes (years) 19 (10 to 30) 5 (1 to 11) 1.29 (1.18-1.40) 1.17 (1.14-1.20) 1.10 (1.01-1.20) 0.04 
Retinopathy 7900 (30.2%) 36410 (12.6%) 0.66 (0.48-0.92) 1.15 (1.07-1.23) 0.58 (0.41-0.80) 0.001 
Summary statistics are the number (percentage), mean (standard deviation), and median (interquartile range) for risk factors which are categorical, 
symmetrical and skewed continuous variables respectively. The odds ratios (and 95% confidence intervals) are for the odds of heart failure within 3-
years for people with type 1 and type 2 diabetes, along with an interaction odds ratio for the difference in odds ratio between people with type 1 and 
type 2 diabetes. The P-value for the interaction is also shown. Deprivation is coded from least to most deprived. All continuous variables were 
standardised so that the odds ratio can be interpreted as the increase in odds per standard deviation increment. All variables in the table were included in 
the model with the exception of LDL cholesterol because this was not measured in large proportion of patients, and diastolic blood pressure because 
this is likely to be collinear with systolic blood pressure. The extent of missing data and approach to missingness are documented in the supplementary 
appendix. 
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Table 4 Cardiovascular drugs in people with diabetes 
 
 Summary statistics Odds ratio for drug prescription in type 2  
versus type 1 
Drug Type 1 Type 2 Unadjusted Model 1 Model 2 
Thiazides 1349 (5.2%) 47228 (16.4%) 3.61 (3.41-3.82) 2.17 (2.04-2.29) 2.11 (1.99-2.23) 
Loop 1174 (4.5%) 31623 (11%) 2.63 (2.47-2.79) 0.87 (0.82-0.93) 0.88 (0.82-0.94) 
Potassium sparing 197 (0.8%) 7055 (2.4%) 3.31 (2.87-3.82) 1.78 (1.53-2.05) 1.68 (1.45-1.94) 
Beta blockers 1996 (7.6%) 75105 (26.1%) 4.27 (4.08-4.47) 2.15 (2.05-2.25) 1.97 (1.88-2.07) 
Renin-Angiotensin System Drugs 7563 (28.9%) 145304 (50.4%) 2.50 (2.44-2.57) 1.33 (1.29-1.37) 1.14 (1.1-1.17) 
Nitrates and other anti-anginal 653 (2.5%) 24183 (8.4%) 3.58 (3.31-3.88) 1.55 (1.43-1.68) 1.50 (1.38-1.63) 
Calcium-Channel Blockers 2637 (10.1%) 72817 (25.3%) 3.02 (2.9-3.15) 1.59 (1.52-1.66) 1.48 (1.41-1.54) 
Anticoagulants 249 (1%) 14386 (5%) 5.47 (4.83-6.21) 1.82 (1.6-2.07) 1.74 (1.53-1.98) 
Antiplatelets 4079 (15.6%) 94631 (32.8%) 2.65 (2.56-2.74) 1.03 (0.99-1.07) 0.90 (0.87-0.94) 
Lipid lowering drugs 9222 (35.2%) 178100 (61.8%) 2.98 (2.9-3.06) 1.39 (1.35-1.43) 1.21 (1.18-1.25) 
N (%) of people currently prescribed at least one drug the relevant class at the start of the closed cohort, October 1st 2013. Odds 
ratios (95% CIs) that drug is prescribed in people with type 2 versus type 1 diabetes. Each drug-class was modelled separately, 
unadjusted, adjusted for age and sex (model 1) and adjusted for the predicted risk of heart failure (model 2). The predicted risk in 
model 2 was obtained from the full set of model coefficients for the full models shown in Table 3, and hence is based on each 
patient’s baseline characteristics (age, sex, deprivation, duration of diabetes, body mass index, smoking status, previous stroke, 
previous myocardial infarction, systolic blood pressure total and HDL cholesterol, HbA1c, estimated glomerular filtration rate 
and retinopathy). See supplementary appendix for the approach used to classify drugs. 
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Figure Legends 
 
Figure 1. Age, sex and deprivation adjusted incidence of heart failure hospitalisation by 
diabetes type, age and sex 
The lines represent the predicted rates obtained from quasi-Poisson regression models of incident 
heart failure events. The ribbons are 95% confidence intervals. Covariates included in the model 
were age, sex, deprivation and diabetes type, with interaction terms included where these 
improved model fit. Predictions were made at the median deprivation score. Points represent 
event rates stratified by age (in years), sex and diabetes type. Models are given in full in the 
supplementary appendix. 
 
Figure 2. Age, sex and deprivation adjusted trends in incident heart failure hospitalisation 
by diabetes type, sex and calendar-year 
The lines represent the predicted rates obtained from generalized additive models of incident 
heart failure events. The ribbons are 95% confidence intervals. Covariates included in the model 
were age, sex, deprivation, diabetes type and calendar-year, with interaction terms included 
where these improved model fit. The model was fit with a log-link and Poisson likelihood, with 
correction of the standard errors for overdispersion. Penalized thin plate regression splines were 
used to model non-linear associations for calendar-year by diagnosis type. Predictions were 
made for men and women aged 50 (as this was the closest decade to the mean age in the general 
population). Models are given in full in the supplementary appendix. See https://ihwph-
hehta.shinyapps.io/dm_hf_fig2/ for an interactive version of this plot. 
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Figure 3. Age, sex and deprivation adjusted 30-day case-fatality of incident heart failure 
hospitalisation by age, sex and diabetes type 
The lines represent the predicted case-fatality proportions obtained from logistic regression 
models of death. Covariates included in the model were age, sex, deprivation and diabetes type, 
with interaction terms included where these improved model fit. Predictions were made at the 
median deprivation score. Points represent case-fatality proportions stratified by age, sex and 
diabetes type, with the point size being proportional to the number in the denominator. Models 
are given in full in the supplementary appendix. 
Figure 4. Age, sex and deprivation adjusted trends in 30-day case-fatality of incident heart 
failure hospitalisation 
The lines represent the predicted rates obtained from generalized additive models of heart failure 
30-day case-fatality on age, sex, deprivation, diabetes type and calendar-year, with interaction
terms included where these improved model fit, using a logit-link and binomial likelihood. 
Predictions were made for men and women aged 50 (as this was the closest decade to the mean 
age in the general population). Models are given in full in the supplementary appendix. 
Figure 5. Age, sex and deprivation adjusted incidence of heart failure hospitalisation by 
diabetes type, age and sex in people without previous ischaemic heart disease 
The lines represent the predicted rates obtained from quasi-Poisson regression models of incident 
heart failure events. The ribbons are 95% confidence intervals. Covariates included in the model 
were age, sex, deprivation and diabetes type, with interaction terms included where these 
improved model fit. Predictions were made at the median deprivation score. Points represent 
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event rates stratified by age (in years), sex and diabetes type. Models are given in full in the 
supplementary appendix. 
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Aggregated data
Table S1 Heart failure admissions by age, sex, deprivation and diagnosis
Age Sex Deprivation Diagnosis Admissions Persontime
20 to 49 men 1-5 No diabetes 1087 5069751
20 to 49 men 1-5 Type1 40 41394
20 to 49 men 1-5 Type 2 86 49255
20 to 49 men 6-10 No diabetes 2065 5263772
20 to 49 men 6-10 Type1 77 44487
20 to 49 men 6-10 Type 2 176 76730
20 to 49 women 1-5 No diabetes 433 5249525
20 to 49 women 1-5 Type1 29 30875
20 to 49 women 1-5 Type 2 31 31915
20 to 49 women 6-10 No diabetes 945 5601676
20 to 49 women 6-10 Type1 46 32760
20 to 49 women 6-10 Type 2 103 58611
50 to 59 men 1-5 No diabetes 2055 1693189
50 to 59 men 1-5 Type1 46 12610
50 to 59 men 1-5 Type 2 385 99307
2
Age Sex Deprivation Diagnosis Admissions Persontime
50 to 59 men 6-10 No diabetes 2955 1458296
50 to 59 men 6-10 Type1 98 11905
50 to 59 men 6-10 Type 2 708 123769
50 to 59 women 1-5 No diabetes 704 1794524
50 to 59 women 1-5 Type1 39 8931
50 to 59 women 1-5 Type 2 145 56955
50 to 59 women 6-10 No diabetes 1416 1569962
50 to 59 women 6-10 Type1 69 8380
50 to 59 women 6-10 Type 2 303 87522
60 to 69 men 1-5 No diabetes 3812 1263936
60 to 69 men 1-5 Type1 75 7191
60 to 69 men 1-5 Type 2 1175 145099
60 to 69 men 6-10 No diabetes 5353 1124748
60 to 69 men 6-10 Type1 97 6804
60 to 69 men 6-10 Type 2 1883 163745
60 to 69 women 1-5 No diabetes 1865 1411898
60 to 69 women 1-5 Type1 49 6010
60 to 69 women 1-5 Type 2 500 92678
60 to 69 women 6-10 No diabetes 3257 1287385
60 to 69 women 6-10 Type1 79 5690
60 to 69 women 6-10 Type 2 1134 132674
70 to 79 men 1-5 No diabetes 5934 741182
70 to 79 men 1-5 Type1 87 3469
70 to 79 men 1-5 Type 2 2121 121589
70 to 79 men 6-10 No diabetes 7511 704085
70 to 79 men 6-10 Type1 114 3372
70 to 79 men 6-10 Type 2 2743 135025
70 to 79 women 1-5 No diabetes 4479 943917
70 to 79 women 1-5 Type1 82 3766
70 to 79 women 1-5 Type 2 1383 103576
70 to 79 women 6-10 No diabetes 7232 987117
70 to 79 women 6-10 Type1 102 3962
70 to 79 women 6-10 Type 2 2445 142301
80 to 89 men 1-5 No diabetes 7690 339174
80 to 89 men 1-5 Type1 35 899
80 to 89 men 1-5 Type 2 1737 49383
80 to 89 men 6-10 No diabetes 7878 314140
80 to 89 men 6-10 Type1 38 833
80 to 89 men 6-10 Type 2 1717 46507
80 to 89 women 1-5 No diabetes 11513 640946
80 to 89 women 1-5 Type1 48 1251
80 to 89 women 1-5 Type 2 1843 64392
80 to 89 women 6-10 No diabetes 13245 653518
80 to 89 women 6-10 Type1 63 1334
80 to 89 women 6-10 Type 2 2341 74249
Numbers less than or equal to 5 were suppressed to maintain confidentiality.
Table S2 Heart failure deaths within 30 days of admission by age, sex, deprivation
and diagnosis
3
Age Sex Deprivation Diagnosis Admissions Deaths
20 to 29 men 1-5 pop 75 <=5
20 to 29 men 1-5 t1dm <=5 <=5
20 to 29 men 1-5 t2dm <=5 <=5
20 to 29 men 6-10 pop 124 <=5
20 to 29 men 6-10 t1dm 6 <=5
20 to 29 men 6-10 t2dm <=5 <=5
20 to 29 women 1-5 pop 51 <=5
20 to 29 women 1-5 t1dm <=5 <=5
20 to 29 women 6-10 pop 79 <=5
20 to 29 women 6-10 t1dm <=5 <=5
20 to 29 women 6-10 t2dm <=5 <=5
30 to 49 men 1-5 pop 1012 31
30 to 49 men 1-5 t1dm 36 6
30 to 49 men 1-5 t2dm 85 <=5
30 to 49 men 6-10 pop 1941 100
30 to 49 men 6-10 t1dm 71 <=5
30 to 49 men 6-10 t2dm 173 <=5
30 to 49 women 1-5 pop 382 26
30 to 49 women 1-5 t1dm 27 <=5
30 to 49 women 1-5 t2dm 31 <=5
30 to 49 women 6-10 pop 866 71
30 to 49 women 6-10 t1dm 41 <=5
30 to 49 women 6-10 t2dm 98 6
50 to 59 men 1-5 pop 2055 76
50 to 59 men 1-5 t1dm 46 <=5
50 to 59 men 1-5 t2dm 385 23
50 to 59 men 6-10 pop 2955 181
50 to 59 men 6-10 t1dm 98 10
50 to 59 men 6-10 t2dm 708 46
50 to 59 women 1-5 pop 704 30
50 to 59 women 1-5 t1dm 39 <=5
50 to 59 women 1-5 t2dm 145 10
50 to 59 women 6-10 pop 1416 126
50 to 59 women 6-10 t1dm 69 7
50 to 59 women 6-10 t2dm 303 28
60 to 69 men 1-5 pop 3812 264
60 to 69 men 1-5 t1dm 75 14
60 to 69 men 1-5 t2dm 1175 76
60 to 69 men 6-10 pop 5353 453
60 to 69 men 6-10 t1dm 97 15
60 to 69 men 6-10 t2dm 1883 160
60 to 69 women 1-5 pop 1865 175
60 to 69 women 1-5 t1dm 49 <=5
60 to 69 women 1-5 t2dm 500 39
60 to 69 women 6-10 pop 3257 390
60 to 69 women 6-10 t1dm 79 10
60 to 69 women 6-10 t2dm 1134 119
70 to 79 men 1-5 pop 5934 684
70 to 79 men 1-5 t1dm 87 17
70 to 79 men 1-5 t2dm 2121 261
70 to 79 men 6-10 pop 7511 1001
70 to 79 men 6-10 t1dm 114 23
4
Age Sex Deprivation Diagnosis Admissions Deaths
70 to 79 men 6-10 t2dm 2743 326
70 to 79 women 1-5 pop 4479 578
70 to 79 women 1-5 t1dm 82 17
70 to 79 women 1-5 t2dm 1383 166
70 to 79 women 6-10 pop 7232 997
70 to 79 women 6-10 t1dm 102 13
70 to 79 women 6-10 t2dm 2445 321
80 to 89 men 1-5 pop 7690 1531
80 to 89 men 1-5 t1dm 35 10
80 to 89 men 1-5 t2dm 1737 307
80 to 89 men 6-10 pop 7878 1579
80 to 89 men 6-10 t1dm 38 13
80 to 89 men 6-10 t2dm 1717 322
80 to 89 women 1-5 pop 11513 2260
80 to 89 women 1-5 t1dm 48 10
80 to 89 women 1-5 t2dm 1843 350
80 to 89 women 6-10 pop 13245 2627
80 to 89 women 6-10 t1dm 63 14
80 to 89 women 6-10 t2dm 2341 440
Classification of drugs
All drugs for people with diabetes are incldued in the Scottish diabetes register, having been extracted
from primary care records. These are assigned to a British National Formulary (BNF) chapter, section
and paragraph heading. We collapsed the BNF headings to each of the groups shown in Table S3. See
https://openprescribing.net/bnf/ for a complete list of headings. Patients were counted as having been
prescribed the drug if they were currently prescribed a drug within that class on the cohort start date, the
1st of October 2013.
Table S3 Prescribed drugs, groups each BNF heading assigned to
BNF heading BNF heading label Group
2.2.1 Thiazides And Related Diuretics Thiazides
2.2.2 Loop Diuretics Loop
2.2.3 Pot-Sparing Diuretics&Aldosterone Antag Potassium sparing
2.2.4 Potassium Sparing Diuretics & Compounds Potassium sparing
2.4 Beta-Adrenoceptor Blocking Drugs Beta blockers
2.5.5 Renin-Angiotensin System Drugs Renin-Angiotensin System Drugs
2.6.1 Nitrates Nitrates and other anti-anginal
2.6.2 Calcium-Channel Blockers Calcium-Channel Blockers
2.6.3 Other Antianginal Drugs Nitrates and other anti-anginal
2.8.2 Oral Anticoagulants Anticoagulants
2.9 Antiplatelet Drugs Antiplatelets
2.12 Lipid-Regulating Drugs Lipid lowering drugs
5
Incidence rate calculation using a look-back period
Figure S1 shows a worked example for the calculation of events and person-time for a notional population
stratum. For example, men born in 1968 who did not have diabetes. In this example, 3 people had one or
more admission with heart failure during the follow-up period, and/or during the 10 year look-back period.
The calculation of year-specific incident counts is straightforward, and is shown alongside the figure. Any
event after the start of the cohort period, where there was no previous event within 10 years is considered
incident and this is summed across rows.
The person-years calculation is more complex and is shown in Tables S4 and S5.
Figure S1 Admissions and incident events in 3 example patients
A - admission, I incident event.
Table S4 components of person time calculation
6
Year POP DM p1 p2 p3
2004 190 10 0 1 0
2005 190 10 0 1 0
2006 190 10 1 1 0
2007 190 10 1 1 0
2008 190 10 1 1 0
2009 190 12 1 1 0
2010 190 12 1 1 0
2011 185 12 0 0 0
2012 185 12 0 0 0
2013 185 13 0 0 1
POP refers to the mid-year estimate for the population (based on National Records Scotland census data
and mid-year estimation modelling ). DM refers to the population with diabetes (from the diabetes register)
and p1, p2 and p3 refers to the person-time for the 3 patients.
Since patient 1 had an admission in 1995, they were not eligible to have another incident event within ten
years, and so the person-time for each of these periods is removed. Patient 2 had an incident event in 2011
and so only contributed 7 person-years. Patient 3 had an event in 2003 which was not incident, and as a
consequence contributed only one person year.
The person-time for each year, within each stratum, is calculated as follows:-
PT = POP − DM − N + p1 + p2 + p3 + ...pn
Where POP , DM and pn are as per Table S4 and N indicates the number of patients with events observed.
In R, for this example, this would be calculated as follows, along with the calendar-year/stratum-specific
rate.
pt_ill2 <- pt_ill %>%
mutate(`Person time` = POP - DM - 3 + p1 + p2 + p3,
`Rate per 1000 person-years` = 1000* Incident/`Person time`)
Table S5 person time and rate calculation
Year POP DM p1 p2 p3 Incident Person time Rate per 1000 person-years
2004 190 10 0 1 0 0 178 0.0
2005 190 10 0 1 0 0 178 0.0
2006 190 10 1 1 0 0 179 0.0
2007 190 10 1 1 0 0 179 0.0
2008 190 10 1 1 0 0 179 0.0
2009 190 12 1 1 0 0 177 0.0
2010 190 12 1 1 0 0 177 0.0
2011 185 12 0 0 0 2 170 11.8
2012 185 12 0 0 0 0 170 0.0
2013 185 13 0 0 1 0 170 0.0
7
Missing data and imputation for risk factor data
For the cohort with diabetes identified in 2013, there was missing data for a number of variables (Table S6).
Table S6 Proportion of missing data for each variable for the 2013 cohort of
people with type 1 and type 2 diabetes, used to estimate associations with clinical
risk factors
Type 2 Type 1
Age 0% 0%
BMI 20.1% 16.4%
Deprivation (Deciles) 0% 0%
Diastolic BP 7.5% 9.1%
EGFR 39.8% 42.5%
HbA1 17.6% 11.2%
HDL 18.8% 19.2%
LDL 71.1% 57.9%
Retinopathy 0% 0%
Sex 0% 0%
Smoking status 9.2% 8.9%
Systolic BP 7.5% 9.1%
Total cholesterol 11.1% 13%
Summary statistics for each variable are reported (in Table 3 in the main manuscript) based on the available
data for each variable. For the logistic regression models, we carried out multiple imputation, using the
MICE package in R.1
We obtained 5 imputed datasets, using all the variables included in the planned model as well as LDL
cholesterol and diastolic blood pressure. Imputation was performed using the following methods for each
variable-type:- predictive mean matching for continuous variables, logistic regression for binary variables,
polytomous regression for unordered categorical variables and proportional odds model for ordered categorical
variables.
We then fit a logistic regression model to each imputed dataset and pooled the results using the method
described by Barnard and Rubin.2 Results of the modelling are shown in Table 3 of the main manscript.
8
Main analysis - additional tables and figures
Figure S2 Prevalence of heart failure by diabetes type, age and sex
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The lines represent the predicted prevalences obtained from logistic regression models of prevalent heart
failure events on age, sex, deprivation and diabetes type, with interaction terms included where these
improved model fit. Predictions were made at the median deprivation score.
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Figure S3 Prevalence of heart failure by diabetes type, deprivation and sex
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The lines represent the predicted prevalences obtained from logistic regression models of prevalent heart
failure events on age, sex, deprivation and diabetes type, with interaction terms included where these
improved model fit. Predictions were made at age 50.
Table S7 Cross-sectional prevalence model, coefficients and standard errors
Estimate Std. Error t value Pr(>|t|)
(Intercept) -7.28 0.045 -161.023 <0.001
age_ten 1.371 0.016 87.729 <0.001
sex -1.173 0.048 -24.383 <0.001
dep_two 0.948 0.03 31.527 <0.001
typet1dm 1.884 0.275 6.846 <0.001
typet2dm 1.767 0.134 13.194 <0.001
age_ten:sex 0.156 0.012 13.405 <0.001
age_ten:dep_two -0.205 0.01 -19.533 <0.001
sex:dep_two 0.153 0.024 6.32 <0.001
age_ten:typet1dm -0.196 0.109 -1.788 0.074
age_ten:typet2dm -0.57 0.051 -11.209 <0.001
sex:typet1dm 0.999 0.327 3.058 0.002
sex:typet2dm 1.001 0.142 7.052 <0.001
dep_two:typet1dm -0.399 0.189 -2.11 0.035
dep_two:typet2dm -0.464 0.091 -5.093 <0.001
age_ten:sex:typet1dm -0.312 0.081 -3.835 <0.001
age_ten:sex:typet2dm -0.145 0.039 -3.747 <0.001
age_ten:dep_two:typet1dm 0.039 0.074 0.523 0.601
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Estimate Std. Error t value Pr(>|t|)
age_ten:dep_two:typet2dm 0.138 0.035 3.949 <0.001
sex:dep_two:typet1dm 0.096 0.205 0.467 0.641
sex:dep_two:typet2dm -0.241 0.073 -3.325 0.001
Logistic regression model with admission as the outcome. Age_ten is the age in years divided by ten and
dep_two is the deprivation score divided by two.
Figure S4 Incidence rate of heart failure by diabetes type, deprivation and sex
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The lines represent the predicted rates obtained from quasi-Poisson regression models of incident heart
failure events on age, sex, deprivation and diabetes type, with interaction terms included where these
improved model fit. Predictions were made for men and women aged 50.
Table S8 Cross-sectional incidence rate model, coefficients and standard errors
Estimate Std. Error t value Pr(>|t|)
(Intercept) -7.742 0.021 -372.393 <0.001
age_ten 1.131 0.007 154.279 <0.001
sex -1.023 0.023 -45.447 <0.001
dep_two 0.683 0.014 47.613 <0.001
typet1dm 1.491 0.117 12.765 <0.001
typet2dm 1.518 0.053 28.734 <0.001
age_ten:sex 0.162 0.006 28.1 <0.001
age_ten:dep_two -0.167 0.005 -32.915 <0.001
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Estimate Std. Error t value Pr(>|t|)
sex:dep_two 0.11 0.012 9.364 <0.001
age_ten:typet1dm -0.177 0.054 -3.294 0.001
age_ten:typet2dm -0.289 0.02 -14.751 <0.001
sex:typet1dm 0.824 0.087 9.479 <0.001
sex:typet2dm 0.494 0.042 11.852 <0.001
dep_two:typet1dm -0.111 0.079 -1.413 0.158
dep_two:typet2dm -0.235 0.037 -6.433 <0.001
age_ten:sex:typet1dm -0.204 0.041 -5.013 <0.001
age_ten:sex:typet2dm -0.114 0.015 -7.363 <0.001
age_ten:dep_two:typet1dm 0.047 0.036 1.301 0.193
age_ten:dep_two:typet2dm 0.053 0.014 3.919 <0.001
Quasi-Poisson regression model with admissions or death as the outcome. Age_ten is the age in years divided
by ten and dep_two is the deprivation score divided by two. The standard errors and P-values are scaled to
allow for overdispersion.
Figure S5 Modelled rate of heart failure by diabetes type, deprivation and sex.
Rates shown on absolute scale
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This figure is is simiar to Figure one in the main manuscript, using the same regression model, but with
deprivation rather than age being shown on the x-axis. The lines represent the predicted rates obtained from
quasi-Poisson regression models of incident heart failure events on age, sex, deprivation and diabetes type,
with interaction terms included where these improved model fit. Predictions were made at age 50.
Table S9 Time trends incidence rate model, coefficients and standard errors
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Estimate Std. Error t value Pr(>|t|)
(Intercept) -7.738 0.021 -373.826 <0.001
age_ten 1.135 0.007 155.51 <0.001
sex -1.024 0.022 -45.789 <0.001
dep_two 0.682 0.014 47.877 <0.001
year -0.009 0.003 -3.774 <0.001
typet1dm 1.511 0.116 13.031 <0.001
typet2dm 1.521 0.053 28.946 <0.001
age_ten:sex 0.161 0.006 28.112 <0.001
age_ten:dep_two -0.168 0.005 -33.366 <0.001
sex:dep_two 0.111 0.012 9.485 <0.001
age_ten:year -0.005 0.001 -5.481 <0.001
age_ten:typet1dm -0.181 0.053 -3.399 0.001
age_ten:typet2dm -0.287 0.02 -14.714 <0.001
sex:typet1dm 0.823 0.086 9.549 <0.001
sex:typet2dm 0.493 0.041 11.896 <0.001
dep_two:typet1dm -0.116 0.078 -1.489 0.137
dep_two:typet2dm -0.234 0.036 -6.453 <0.001
year:typet1dm -0.022 0.01 -2.125 0.034
year:typet2dm -0.004 0.003 -1.481 0.139
age_ten:sex:typet1dm -0.206 0.04 -5.102 <0.001
age_ten:sex:typet2dm -0.113 0.015 -7.399 <0.001
age_ten:dep_two:typet1dm 0.047 0.036 1.306 0.192
age_ten:dep_two:typet2dm 0.054 0.014 4.002 <0.001
Quasi-Poisson regression model with admissions or death as the outcome. Age_ten is the age in years divided
by ten and dep_two is the deprivation score divided by two. The standard errors and P-values are scaled to
allow for overdispersion.
Table S10 Estimates of non-parametric smooth functions
Estimated degrees of freedom Chi-squared Approximate P-value
No diabetes 7.825 453.517 <0.001
Type 1 1.916 17.512 <0.001
Type 2 2.15 117.707 <0.001
Significance tests for the non-parametric smooth terms from a generalized additive model of incident heart
failure events on age, sex, deprivation, diabetes type and calendar year, with interaction terms included where
these improved model fit, using a log-link and Poisson likelihood, with correction of the standard errors for
overdispersion. Penalized thin plate regression splines were used to model non-linear associations for calendar
year by diagnosis type. Predictions were made for men and women aged 50.
Table S11, Heart failure case-fatality model, coefficients and standard errors
Estimate Std. Error z value Pr(>|z|)
(Intercept) -2.938 0.037 -79.507 <0.001
age_ten 0.239 0.024 10.07 <0.001
I(age_tenˆ2) 0.041 0.005 7.985 <0.001
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Estimate Std. Error z value Pr(>|z|)
sex 0.041 0.02 2.077 0.038
dep_two 0.113 0.016 7.317 <0.001
typet1dm 0.649 0.104 6.248 <0.001
typet2dm -0.046 0.031 -1.483 0.138
sex:typet1dm -0.375 0.158 -2.377 0.017
sex:typet2dm 0.021 0.044 0.485 0.628
Logistic regression model with death as the outcome and admission or death as the denominator. Age_ten is
the age in years divided by ten and dep_two is the deprivation score divided by two.
Table S12, Heart failure case-fatality over time model, coefficients and standard
errors
Estimate Std. Error z value Pr(>|z|)
(Intercept) -2.917 0.037 -79.47 <0.001
age_ten 0.23 0.024 9.696 <0.001
I(age_tenˆ2) 0.044 0.005 8.521 <0.001
sex 0.036 0.018 2.064 0.039
dep_two 0.108 0.016 6.988 <0.001
year -0.033 0.003 -10.135 <0.001
typet1dm 0.47 0.079 5.976 <0.001
typet2dm -0.017 0.023 -0.768 0.442
year:typet1dm 0.01 0.027 0.38 0.704
year:typet2dm -0.006 0.008 -0.817 0.414
Logistic regression model with death as the outcome and admission or death as the denominator. Age_ten is
the age in years divided by ten and dep_two is the deprivation score divided by two.
Additional analysis - IHD admissions excluded
Table S13 Heart failure admissions and deaths by age, sex, deprivation and
diagnosis with IHD admissions excluded
Age Sex Deprivation Diagnosis Admissions Persontime
20 to 49 men 1-5 No diabetes 901 5069826
20 to 49 men 1-5 Type1 29 41407
20 to 49 men 1-5 Type 2 78 49272
20 to 49 men 6-10 No diabetes 1692 5263834
20 to 49 men 6-10 Type1 50 44543
20 to 49 men 6-10 Type 2 138 76831
20 to 49 women 1-5 No diabetes 397 5249540
20 to 49 women 1-5 Type1 diff 30878
20 to 49 women 1-5 Type 2 diff 31920
20 to 49 women 6-10 No diabetes 822 5601684
20 to 49 women 6-10 Type1 35 32785
20 to 49 women 6-10 Type 2 77 58653
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Age Sex Deprivation Diagnosis Admissions Persontime
50 to 59 men 1-5 No diabetes 1587 1693233
50 to 59 men 1-5 Type1 28 12659
50 to 59 men 1-5 Type 2 310 99493
50 to 59 men 6-10 No diabetes 2141 1458332
50 to 59 men 6-10 Type1 56 11988
50 to 59 men 6-10 Type 2 546 124173
50 to 59 women 1-5 No diabetes 588 1794491
50 to 59 women 1-5 Type1 24 8981
50 to 59 women 1-5 Type 2 117 57015
50 to 59 women 6-10 No diabetes 1123 1569973
50 to 59 women 6-10 Type1 47 8417
50 to 59 women 6-10 Type 2 246 87663
60 to 69 men 1-5 No diabetes 2834 1263927
60 to 69 men 1-5 Type1 50 7243
60 to 69 men 1-5 Type 2 871 145751
60 to 69 men 6-10 No diabetes 3678 1124789
60 to 69 men 6-10 Type1 63 6891
60 to 69 men 6-10 Type 2 1424 164762
60 to 69 women 1-5 No diabetes 1489 1411856
60 to 69 women 1-5 Type1 30 6061
60 to 69 women 1-5 Type 2 364 92946
60 to 69 women 6-10 No diabetes 2409 1287403
60 to 69 women 6-10 Type1 52 5749
60 to 69 women 6-10 Type 2 862 133206
70 to 79 men 1-5 No diabetes 3982 741231
70 to 79 men 1-5 Type1 45 3528
70 to 79 men 1-5 Type 2 1559 122825
70 to 79 men 6-10 No diabetes 4860 704115
70 to 79 men 6-10 Type1 72 3448
70 to 79 men 6-10 Type 2 1962 136811
70 to 79 women 1-5 No diabetes 3334 943974
70 to 79 women 1-5 Type1 49 3833
70 to 79 women 1-5 Type 2 1042 104267
70 to 79 women 6-10 No diabetes 5120 987247
70 to 79 women 6-10 Type1 67 4025
70 to 79 women 6-10 Type 2 1833 143606
80 to 89 men 1-5 No diabetes 5219 340043
80 to 89 men 1-5 Type1 19 929
80 to 89 men 1-5 Type 2 1284 50231
80 to 89 men 6-10 No diabetes 5336 314982
80 to 89 men 6-10 Type1 26 856
80 to 89 men 6-10 Type 2 1284 47422
80 to 89 women 1-5 No diabetes 8582 642195
80 to 89 women 1-5 Type1 28 1271
80 to 89 women 1-5 Type 2 1412 65181
80 to 89 women 6-10 No diabetes 9563 654989
80 to 89 women 6-10 Type1 46 1353
80 to 89 women 6-10 Type 2 1739 75363
Numbers less than or equal to 5, or where the difference from Table S1 is less than or equal to 5 were
suppressed to maintain confidentiality.
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Figure S6 Modelled rate of heart failure by diabetes type, age and sex with IHD
admissions excluded
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The lines represent the predicted rates obtained from quasi-Poisson regression models of incident heart
failure events on age, sex, deprivation and diabetes type, with interaction terms included where these
improved model fit. Predictions were made at the median deprivation score. Points represent event rates
stratified by age (in years), sex and diabetes type.
Table S14 Cross-sectional model, coefficients and standard errors with IHD ad-
missions excluded
Estimate Std. Error t value Pr(>|t|)
(Intercept) -7.945 0.024 -326.852 <0.001
age_ten 1.079 0.009 124.583 <0.001
sex -0.956 0.027 -36.019 <0.001
dep_two 0.621 0.017 36.802 <0.001
typet1dm 1.329 0.144 9.237 <0.001
typet2dm 1.481 0.062 23.86 <0.001
age_ten:sex 0.173 0.007 25.265 <0.001
age_ten:dep_two -0.158 0.006 -26.279 <0.001
sex:dep_two 0.105 0.014 7.368 <0.001
age_ten:typet1dm -0.222 0.068 -3.254 0.001
age_ten:typet2dm -0.261 0.023 -11.256 <0.001
sex:typet1dm 0.855 0.108 7.927 <0.001
sex:typet2dm 0.43 0.049 8.763 <0.001
dep_two:typet1dm -0.113 0.098 -1.161 0.246
dep_two:typet2dm -0.187 0.043 -4.361 <0.001
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Estimate Std. Error t value Pr(>|t|)
age_ten:sex:typet1dm -0.221 0.052 -4.29 <0.001
age_ten:sex:typet2dm -0.112 0.018 -6.158 <0.001
age_ten:dep_two:typet1dm 0.089 0.046 1.928 0.054
age_ten:dep_two:typet2dm 0.044 0.016 2.753 0.006
Quasi-Poisson regression model with admissions or death as the outcome. Age_ten is the age in years divided
by ten and dep_two is the deprivation score divided by two. The standard errors and P-values are scaled to
allow for overdispersion.
Figure S7 Trends in rates of heart failure by diabetes type, sex and calendar
year with IHD admissions excluded
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The lines represent the predicted rates obtained from generalized additive models of incident heart failure
events on age, sex, deprivation, diabetes type and calendar year, with interaction terms included where
these improved model fit, using a log-link and Poisson likelihood, with correction of the standard errors for
overdispersion. Penalized thin plate regression splines were used to model non-linear associations for calendar
year by diagnosis type. Predictions were made for men and women aged 50.
Table S15 Time trends model, coefficients and standard errors with IHD admis-
sions excluded
Estimate Std. Error t value Pr(>|t|)
(Intercept) -7.941 0.024 -327.026 <0.001
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Estimate Std. Error t value Pr(>|t|)
age_ten 1.082 0.009 125.008 <0.001
sex -0.957 0.026 -36.164 <0.001
dep_two 0.621 0.017 36.892 <0.001
year -0.006 0.003 -2.127 0.033
typet1dm 1.343 0.144 9.36 <0.001
typet2dm 1.486 0.062 23.988 <0.001
age_ten:sex 0.172 0.007 25.252 <0.001
age_ten:dep_two -0.158 0.006 -26.502 <0.001
sex:dep_two 0.105 0.014 7.426 <0.001
age_ten:year -0.003 0.001 -3.302 0.001
age_ten:typet1dm -0.224 0.068 -3.301 0.001
age_ten:typet2dm -0.258 0.023 -11.183 <0.001
sex:typet1dm 0.854 0.107 7.955 <0.001
sex:typet2dm 0.428 0.049 8.763 <0.001
dep_two:typet1dm -0.117 0.097 -1.197 0.231
dep_two:typet2dm -0.187 0.043 -4.36 <0.001
year:typet1dm -0.015 0.013 -1.15 0.25
year:typet2dm -0.007 0.003 -2.2 0.028
age_ten:sex:typet1dm -0.222 0.051 -4.335 <0.001
age_ten:sex:typet2dm -0.112 0.018 -6.176 <0.001
age_ten:dep_two:typet1dm 0.089 0.046 1.932 0.053
age_ten:dep_two:typet2dm 0.045 0.016 2.79 0.005
Quasi-Poisson regression model with admissions or death as the outcome. Age_ten is the age in years divided
by ten and dep_two is the deprivation score divided by two. The standard errors and P-values are scaled to
allow for overdispersion.
Table S16 Estimates of non-parametric smooth functions with IHD admissions
excluded
Estimated degrees of freedom Chi-squared Approximate P-value
No diabetes 7.646 214.152 <0.001
Type 1 1.005 4.75 0.03
Type 2 1.968 66.125 <0.001
Significance tests for the non-parametric smooth terms from a generalized additive model of incident heart
failure events on age, sex, deprivation, diabetes type and calendar year, with interaction terms included where
these improved model fit, using a log-link and Poisson likelihood, with correction of the standard errors for
overdispersion. Penalized thin plate regression splines were used to model non-linear associations for calendar
year by diagnosis type.
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Sensitivity analysis - Events coded in First position only
Figure S8 Modelled rate of heart failure by diabetes type, age and sex with
diagnosis recored in first position only
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The lines represent the predicted rates obtained from quasi-Poisson regression models of incident heart
failure events on age, sex, deprivation and diabetes type, with interaction terms included where these
improved model fit. Predictions were made at the median deprivation score. Points represent event rates
stratified by age (in years), sex and diabetes type.
Table S17 Cross-sectional model, coefficients and standard errors with diagnosis
recored in first position only
Estimate Std. Error t value Pr(>|t|)
(Intercept) -9.264 0.039 -236.959 <0.001
age_ten 1.319 0.013 100.519 <0.001
sex -0.864 0.038 -22.468 <0.001
dep_two 0.828 0.026 31.31 <0.001
typet1dm 1.839 0.196 9.38 <0.001
typet2dm 2.031 0.082 24.651 <0.001
age_ten:sex 0.108 0.01 10.731 <0.001
age_ten:dep_two -0.199 0.009 -22.317 <0.001
sex:dep_two 0.107 0.018 5.809 <0.001
age_ten:typet1dm -0.173 0.083 -2.078 0.038
age_ten:typet2dm -0.403 0.03 -13.568 <0.001
sex:typet1dm 0.785 0.14 5.613 <0.001
sex:typet2dm 0.446 0.063 7.124 <0.001
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Estimate Std. Error t value Pr(>|t|)
dep_two:typet1dm -0.119 0.13 -0.916 0.359
dep_two:typet2dm -0.28 0.056 -4.996 <0.001
age_ten:sex:typet1dm -0.217 0.061 -3.537 <0.001
age_ten:sex:typet2dm -0.102 0.023 -4.51 <0.001
age_ten:dep_two:typet1dm 0.05 0.056 0.902 0.367
age_ten:dep_two:typet2dm 0.083 0.02 4.095 <0.001
Quasi-Poisson regression model with admissions or death as the outcome. Age_ten is the age in years divided
by ten and dep_two is the deprivation score divided by two. The standard errors and P-values are scaled to
allow for overdispersion.
Figure S9 Trends in rates of heart failure by diabetes type, sex and calendar
year with with diagnosis recored in first position only
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The lines represent the predicted rates obtained from generalized additive models of incident heart failure
events on age, sex, deprivation, diabetes type and calendar year, with interaction terms included where
these improved model fit, using a log-link and Poisson likelihood, with correction of the standard errors for
overdispersion. Penalized thin plate regression splines were used to model non-linear associations for calendar
year by diagnosis type. Predictions were made for men and women aged 50.
Table S18 Time trends model, coefficients and standard errors with diagnosis
recored in first position only
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Estimate Std. Error t value Pr(>|t|)
(Intercept) -9.25 0.039 -237.045 <0.001
age_ten 1.322 0.013 100.86 <0.001
sex -0.865 0.038 -22.57 <0.001
dep_two 0.826 0.026 31.325 <0.001
year -0.03 0.004 -6.762 <0.001
typet1dm 1.863 0.195 9.548 <0.001
typet2dm 2.04 0.082 24.809 <0.001
age_ten:sex 0.107 0.01 10.652 <0.001
age_ten:dep_two -0.2 0.009 -22.51 <0.001
sex:dep_two 0.108 0.018 5.877 <0.001
age_ten:year 0 0.002 -0.052 0.958
age_ten:typet1dm -0.178 0.083 -2.152 0.031
age_ten:typet2dm -0.401 0.03 -13.517 <0.001
sex:typet1dm 0.784 0.139 5.629 <0.001
sex:typet2dm 0.444 0.063 7.102 <0.001
dep_two:typet1dm -0.125 0.129 -0.971 0.331
dep_two:typet2dm -0.279 0.056 -4.974 <0.001
year:typet1dm -0.025 0.015 -1.683 0.092
year:typet2dm -0.007 0.004 -1.781 0.075
age_ten:sex:typet1dm -0.219 0.061 -3.588 <0.001
age_ten:sex:typet2dm -0.102 0.023 -4.512 <0.001
age_ten:dep_two:typet1dm 0.05 0.055 0.906 0.365
age_ten:dep_two:typet2dm 0.084 0.02 4.135 <0.001
Quasi-Poisson regression model with admissions or death as the outcome. Age_ten is the age in years divided
by ten and dep_two is the deprivation score divided by two. The standard errors and P-values are scaled to
allow for overdispersion.
Table S19 Estimates of non-parametric smooth functions with with diagnosis
recored in first position only
Estimated degrees of freedom Chi-squared Approximate P-value
No diabetes 5.772 294.872 <0.001
Type 1 1.01 15.662 <0.001
Type 2 1.018 127.99 <0.001
Significance tests for the non-parametric smooth terms from a generalized additive model of incident heart
failure events on age, sex, deprivation, diabetes type and calendar year, with interaction terms included where
these improved model fit, using a log-link and Poisson likelihood, with correction of the standard errors for
overdispersion. Penalized thin plate regression splines were used to model non-linear associations for calendar
year by diagnosis type.
Legend for interactive figure
The interactive figure is available at https://ihwph-hehta.shinyapps.io/dm_hf_fig2/.
This figure is an interactive version of Figure 2 which can be found in the main manuscript. The lines
represent the predicted rates obtained from generalized additive models of incident heart failure events. The
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ribbons are 95% confidence intervals. Covariates included in the model were age, sex, deprivation, diabetes
type and calendar-year, with interaction terms included where these improved model fit. The model was fit
with a log-link and Poisson likelihood, with correction of the standard errors for overdispersion. Penalized
thin plate regression splines were used to model non-linear associations for calendar-year by diagnosis type.
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